NL-OMON32748
Completed
Not Applicable
A phase 1 double blind, placebo controlled study of ALX-0141 single dose subcutaneous administration in healthy post-menopausal women - ALX-0141 s.c. SAD study
Ablynx N.V.0 sites42 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Bone loss
- Sponsor
- Ablynx N.V.
- Enrollment
- 42
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy post menopausal women, 18 \- 80 years old, BMI between 18 and 36 kg/m2, moderate or non\-smoker.
Exclusion Criteria
- •Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1\.0 liters of blood in the 10 months prior the start of this study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
A clinical phase I study on GIC-1001 in healthy volunteersGastroenterology/pain management/management of visceral pain during sedation-free colonoscopyDigestive SystemISRCTN09480239gIcare Pharma Inc (Canada)80
Recruiting
Phase 1
A Study to Evaluate the Safety of a Single and Multiple Oral Doses of a Biologic Therapy (MB-001) or placebo in Healthy Human Participantslcerative colitisUlcerative colitisOral and Gastrointestinal - Inflammatory bowel diseaseACTRN12624000524594Mage Biologics48
Active, not recruiting
Phase 1
A Phase 2a, double blind, placebo controlled study to evaluate the efficacy of MEDI-563 in subjects with moderate to severe COPD and sputum eosinophiliaEUCTR2010-020127-52-DKAstraZeneca AB90
Active, not recruiting
Not Applicable
A Phase 2a, double blind, placebo controlled study to evaluate the efficacy of MEDI-563 in subjects with moderate to severe COPD and sputum eosinophiliaChronic obstructive pulmonary disease and Sputum EosinophiliaMedDRA version: 13.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-020127-52-DEAstraZeneca AB90
Active, not recruiting
Phase 1
A Phase 2a, double blind, placebo controlled study to evaluate the efficacy of MEDI-563 in subjects with moderate to severe COPD and sputum eosinophiliaEUCTR2010-020127-52-GBAstraZeneca AB101